Bioventus Cash Flow Statement
NASDAQ: BVSHealth CareMedical/Dental InstrumentsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Bioventus free cash flow
In fiscal 2025, Bioventus generated $74.7 million of operating cash flow and spent $2.6 million on capital expenditures. That left free cash flow of $72.1 million, a free-cash-flow margin of 12.7% of revenue. Free cash flow was up 90.8% from the prior year's $37.8 million.
Summary generated from market data by MetaCap's automated system. Methodology
Bioventus cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 |
|---|---|---|---|---|---|---|---|
| Net Income | 27.27M | -47.05M | -195.63M | -213.39M | 9.59M | 14.72M | 6.30M |
| Net Income growth (YoY) | — | — | — | -2326.07% | -34.89% | +133.76% | — |
| Depreciation & Amortization | 47.01M | 49.55M | 57.37M | 55.40M | 34.88M | 28.64M | 30.32M |
| Stock-Based Compensation | 12.67M | 13.27M | 2.72M | 17.59M | 19.84M | 0 | 0 |
| Change in Working Capital | -12.16M | -9.26M | -1.21M | -39.39M | 1.34M | 16.04M | -9.69M |
| Operating Cash Flow | 74.67M | 38.80M | 15.34M | -13.54M | 22.99M | 71.80M | 40.71M |
| Capital Expenditures | -2.56M | -1.01M | -7.36M | -1.48M | -13.52M | -16.58M | -2.34M |
| Investing Cash Flow | -3.25M | 22.96M | 15.81M | -116.44M | -283.76M | -20.50M | -7.91M |
| Financing Cash Flow | -62.14M | -54.58M | -26.65M | 62.08M | 273.37M | -29.57M | -10.95M |
| Net Change in Cash | 9.66M | 4.62M | 5.13M | -67.38M | 12.37M | 22.32M | 21.75M |
| Free Cash Flow | 72.11M | 37.79M | 7.98M | -15.02M | 9.47M | 55.22M | 38.37M |
This table shows 7 annual periods of Bioventus's cash flow statement, from FY 2025 back to FY 2019, across 10 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow BVS's reporting calendar. What is a cash flow statement?